InsidersTradesSigma
Track the Syndax Pharmaceuticals Inc share price and the full directors' dealings record of the company, a listed issuer based in United States. Shares are quoted on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Syndax Pharmaceuticals Inc has published 81 public disclosures. Market capitalisation: €1.9bn. The latest transaction was filed on 12 June 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: Metzger Michael A. Every trade is accessible without an account.
81
Insider Decl.
n/a
Thresholds
€238,994
5 ops.
Buy Volume
€774,153
8 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Syndax Pharmaceuticals Inc Strong Buy (bullish), based on 12 analysts. Average price target: US$39.00.
52Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 23,619 of 29,055 companies
29.8
score / 100
Value11
Quality48
FCF yld-19%
Earn yld-16%
EV/EBITDA·
ROE-256%
Gross mgn96%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 12 June 2026
Declarations81 total
31,235 shares@ US$18.14290.035% mcap44.1% of flowCommonSEC144:0001959173-26-004618
34,280 shares@ US$17.77810.037% mcap47.4% of flowCommonSEC144:0001959173-26-004566
17,159 shares@ US$21.02811.0% of flowCommon StockSEC:0001193125-26-043814:0
3,410 shares@ US$21.02831.1% of flowCommon StockSEC:0001193125-26-043813:0
73,000 shares0Common StockSEC:0001193125-26-041500:0
24,000 shares0Common StockSEC:0001193125-26-041412:0
24,000 shares0Common StockSEC:0001193125-26-041344:0
24,000 shares0Common StockSEC:0001193125-26-041334:0
48,000 shares0Common StockSEC:0001193125-26-041200:0
24,000 shares0Common StockSEC:0001193125-26-041194:0
24,000 shares0Common StockSEC:0001193125-26-041192:0
24,000 shares0Common StockSEC:0001193125-26-041167:0
1,219 shares@ US$8.484.4% of flowCommon StockSEC:0001193125-26-041497:0
1,224 shares0Common StockSEC:0001193125-25-303941:0
157,307 shares@ US$10.9058.9% of flowCommon StockSEC:0000950170-25-113659:0
19,200 shares@ US$7.2021.9% of flowCommon StockSEC:0000950170-25-109815:0
1,226 shares@ US$8.437.2% of flowCommon StockSEC:0000950170-25-105258:0
1,296 shares@ US$9.2858.9% of flowCommon StockSEC:0000950170-25-096948:0
7,534 shares@ US$9.2855.9% of flowCommon StockSEC:0000950170-25-096947:0
3,000 sharesCommon StockSEC:0000950170-25-074304:0
Canonical exit: 17 Aug 2025 (T+90)
5,000 shares@ US$8.99100.0% of flowCommon StockSEC:0000950170-25-074297:0
Canonical exit: 17 Aug 2025 (T+90)
10,000 shares@ US$9.11229.8% of flowCommon StockSEC:0000950170-25-074289:0
Canonical exit: 17 Aug 2025 (T+90)
11,765 shares@ US$8.995100.0% of flowCommon StockSEC:0000950170-25-074301:0
Canonical exit: 14 Aug 2025 (T+90)
6,074 shares@ US$7.204.2% of flowCommon StockSEC:0000950170-25-039787:0
7,814 shares@ US$7.205.6% of flowCommon StockSEC:0000950170-25-034634:0
25 of 81 declarations
关于 Syndax Pharmaceuticals Inc
Syndax Pharmaceuticals Inc. 是一家在美国纳斯达克上市的美国生物制药公司，股票代码为SNDX，在美国股票市场交易。对于法语投资者而言，Syndax 最好被视为一家商业阶段的肿瘤学专家，而非纯粹的早期生物技术公司。该公司专注于血液癌症及相关适应症的创新疗法，目前拥有两种FDA批准的药物，以及旨在扩大这些资产可及市场的更广泛临床管线。在2025年初关闭其马萨诸塞州沃尔瑟姆办事处后，其主要办事处设在纽约。Syndax于2005年在特拉华州注册成立，尽管其向商业公司的转型相对较晚，但其运营历史悠久。 投资案例以两种主要产品为核心。Revuforj (revumenib) 是一种口服、首创的menin抑制剂。它于2024年11月获得FDA批准，用于治疗伴有KMT2A易位的复发或难治性急性白血病，并于2025年10月获得FDA批准，用于治疗另一种伴有易感NPM1突变的AML人群。第二次批准实质性地扩大了商业和临床机会。Niktimvo (axatilimab-csfr) 是与Incyte合作开发的另一种获批疗法，用于治疗慢性移植物抗宿主病 (GVHD)。这些产品共同使Syndax从一个开发故事转变为一家具有真实商业执行风险和上行潜力的公司，因为价值创造越来越依赖于处方量、上市质量、适应症扩展和持续的证据生成。 在竞争方面，Syndax 相较于大型制药公司仍是一个利基参与者，但在血液肿瘤学领域具有差异化的科学特征。其定位得益于靶向机制、监管认定以及围绕扩大获批用途的重大开发计划。从地理角度来看，商业活动主要集中在美国，而临床和科学足迹则通过主要的血液学和肿瘤学大会扩展到国际。 近期发展尤为重要。2025年，Syndax 展示了 Revuforj 和 Niktimvo 的多项临床数据集，获得了 Revuforj 补充申请的 FDA 优先审查，随后于2025年10月获得了 FDA 批准，将 Revuforj 扩展到第二种 AML 患者群体。该公司还报告称，2025年商业收入加速增长，这突显了从管线选择权到上市执行的转变。对于投资者而言，Syndax 是一家高增长的肿瘤学公司，其商业吸引力、监管跟进和未来适应症扩展是关键催化剂。
